产品描述
Function:
Medical uses
Liraglutide is a once-daily injectable derivative of the human incretin (metabolic hormone) glucagon-like peptide-1 (GLP-1), for the treatment of type 2 diabetes or obesity.
Type 2 diabetes
Liraglutide improves control of blood glucose. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
It acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
It lowers blood triglyceride levels.
- Liraglutide
- DIABETICS
- BLOOD SUGAR
- obesity
- INSULIN
产能:
500000
运输时间表:
立即
Incoterms:
CIF - Cost, Insurance and Freight
EXW - Ex Works
FOB - Free on Board
包装明细:
PE bag+ foil bag+aluminum tin+carton
更多关于
Hybio Pharmaceutical Co., Ltd
500-1000
员工
1
销售额(美元)
40%
% 出口销售额
Year
成立年份
业务类型
- Industry / Manufacturer
- Business Service
关键词
- 多肽原料药
- 制剂
- 利拉鲁肽
- 索马鲁肽
- 阿托西班
- 特利加压素
- 加尼瑞克
- 格拉替雷
- 依替巴肽
- 去氨加压素 Ver Mais
联系方式和位置
- Andrew Li
- +86 xxxxxxxx
- 深圳 / | 中国